Department of Psychiatry, University of California San Diego, CA, United States of America; Sam and Rose Stein Institute for Research on Aging, University of California San Diego, CA, United States of America.
Medical Sciences Division, University of Oxford, Oxford, United Kingdom; Department of Pediatrics, University of California San Diego, CA, United States of America.
Schizophr Res. 2021 Aug;234:24-40. doi: 10.1016/j.schres.2019.08.026. Epub 2019 Sep 5.
Schizophrenia and bipolar disorder (BD) are associated with debilitating psychiatric and cognitive dysfunction, worse health outcomes, and shorter life expectancies. The pathophysiological understanding of and therapeutic resources for these neuropsychiatric disorders are still limited. Humans harbor over 1000 unique bacterial species in our gut, which have been linked to both physical and mental/cognitive health. The gut microbiome is a novel and promising avenue to understand the attributes of psychiatric diseases and, potentially, to modify them. Building upon our previous work, this systematic review evaluates the most recent evidence of the gut microbiome in clinical populations with serious mental illness (SMI). Sixteen articles that met our selection criteria were reviewed, including cross-sectional cohort studies and longitudinal treatment trials. All studies reported alterations in the gut microbiome of patients with SMI compared to non-psychiatric comparison subjects (NCs), and beta-diversity was consistently reported to be different between schizophrenia and NCs. Ruminococcaceae and Faecalibacterium were relatively decreased in BD, and abundance of Ruminococcaceae was reported across several investigations of SMI to be associated with better clinical characteristics. Lactic acid bacteria were relatively more abundant in SMI and associated with worse clinical outcomes. There was very limited evidence for the efficacy of probiotic or prebiotic interventions in SMI. As microbiome research in psychiatry is still nascent, the extant literature has several limitations. We critically evaluate the current data, including experimental approaches. There is a need for more unified methodological standards in order to arrive at robust biological understanding of microbial contributions to SMI.
精神分裂症和双相情感障碍(BD)与严重的精神疾病(SMI)相关的精神和认知功能障碍、更差的健康结果和更短的预期寿命有关。这些神经精神疾病的病理生理学理解和治疗资源仍然有限。人类肠道中存在超过 1000 种独特的细菌物种,这些细菌与身体和心理/认知健康都有关。肠道微生物组是理解精神疾病特征并可能改变这些特征的新的有前途的途径。在我们之前的工作基础上,本系统评价评估了肠道微生物组在有严重精神疾病(SMI)的临床人群中的最新证据。评估了符合我们选择标准的 16 篇文章,包括横断面队列研究和纵向治疗试验。所有研究均报告了 SMI 患者的肠道微生物组与非精神科对照受试者(NCs)相比发生了改变,并且β多样性也被一致报告为精神分裂症与 NCs 之间存在差异。双歧杆菌科和粪杆菌在 BD 中相对减少,并且在几项 SMI 研究中报道了 Ruminococcaceae 的丰度与更好的临床特征相关。乳酸菌在 SMI 中相对更丰富,并与更差的临床结果相关。益生菌或益生元干预在 SMI 中的疗效的证据非常有限。由于精神病学中的微生物组研究仍处于起步阶段,现有文献存在一些局限性。我们批判性地评估了当前的数据,包括实验方法。为了对微生物对 SMI 的贡献有更统一的生物学理解,需要有更统一的方法学标准。